VELMETIA XR 50/1000 sitagliptin (as phosphate monohydrate) 50 mg and metformin hydrochloride1000 mg modified release tablet bottle

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

metformin hydrochloride, Quantity: 1000 mg; sitagliptin phosphate monohydrate, Quantity: 64.25 mg (Equivalent: sitagliptin, Qty 50 mg)

Commercializzato da:

Merck Sharp & Dohme (Australia) Pty Ltd

INN (Nome Internazionale):

Metformin hydrochloride,sitagliptin phosphate monohydrate

Forma farmaceutica:

Tablet, modified release

Composizione:

Excipient Ingredients: povidone; colloidal anhydrous silica; hypromellose; kaolin; propyl gallate; sodium stearylfumarate; macrogol 3350; Carnauba Wax; titanium dioxide; hyprolose; iron oxide yellow; indigo carmine aluminium lake

Via di somministrazione:

Oral

Confezione:

14 tablets - starter pack, 56 tablets

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

VELMETIA XR (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see Sections 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials and 4.2 DOSE AND METHOD OF ADMINISTRATION].

Dettagli prodotto:

Visual Identification: Light green, bi-convex oval, film coated tablet, debossed "80" on one side and plain on the other.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2014-11-19